Does Rallies show Form 4 insider transactions for VNDA?

Yes. Rallies tracks VNDA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is VNDA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VNDA. It does not provide personalized investment advice.

VNDA (Vanda Pharmaceuticals Inc.) Stock Analysis - Insider Trades

Vanda Pharmaceuticals Inc. (VNDA) is a publicly traded Healthcare sector company. As of May 21, 2026, VNDA trades at $6.15 with a market cap of $365.62M and a P/E ratio of -1.52. VNDA moved +2.92% today. Year to date, VNDA is -21.47%; over the trailing twelve months it is +39.19%. Its 52-week range spans $3.81 to $9.94. Analyst consensus is strong buy with an average price target of $16.75. Rallies surfaces VNDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading VNDA stock inside the company?

Recent VNDA insider activity includes Williams Timothy sold 42.43K, Moran Kevin Patrick sold 42.44K, Wijkstrom Joakim sold 30.80K, Polymeropoulos Mihael Hristos sold 156.24K, and Birznieks Gunther sold 42.43K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

VNDA Key Metrics

Key financial metrics for VNDA
Metric	Value
Price	$6.15
Market Cap	$365.62M
P/E Ratio	-1.52
EPS	$-4.05
Dividend Yield	0.00%
52-Week High	$9.94
52-Week Low	$3.81
Volume	1.24K
Avg Volume	0
Revenue (TTM)	$217.78M
Net Income	$-239.55M
Gross Margin	0.00%

Recent VNDA Insider Trades

Williams Timothy sold 42.43K (~$350.76K) on Mar 2, 2026.
Moran Kevin Patrick sold 42.44K (~$350.82K) on Mar 2, 2026.
Wijkstrom Joakim sold 30.80K (~$254.59K) on Mar 2, 2026.
Polymeropoulos Mihael Hristos sold 156.24K (~$1.28M) on Mar 2, 2026.
Birznieks Gunther sold 42.43K (~$350.73K) on Mar 2, 2026.

Latest VNDA News

Vanda Raises 2026 Revenue Outlook to $240–$290M After 26% Fanapt Growth — May 6, 2026
Vanda Demands FDA Revise NAM Guidance Missing Validated Assays, Approval Pathways — Mar 19, 2026
Vanda Pharmaceuticals’ Price Target Raised 21% to $17 from $14 — Feb 26, 2026
Vanda Secures FDA Nod for Bysanti, Psoriasis Drug Eyes December 2026 Decision — Feb 25, 2026
Vanda’s BLA for GPP Therapy Hits FDA Review with Dec. 12, 2026 Deadline — Feb 25, 2026

VNDA Analyst Consensus

4 analysts cover VNDA: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.75.

Common questions about VNDA

Who is trading VNDA stock inside the company?: Recent VNDA insider activity includes Williams Timothy sold 42.43K, Moran Kevin Patrick sold 42.44K, Wijkstrom Joakim sold 30.80K, Polymeropoulos Mihael Hristos sold 156.24K, and Birznieks Gunther sold 42.43K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for VNDA?: Yes. Rallies tracks VNDA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is VNDA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VNDA. It does not provide personalized investment advice.